Immunogenicity of Membrane-Bound Gangliosides in Viable Whole-Cell Vaccines

References

• Morion D L, Ravindranath M H. Active specific immunotherapy with vaccines. Cancer Medicine 4th ed, J F Holland, E Frei, R Bast, D Kufe, D L Morton, R Weichselbaum. Williams & Wilkins, Baltimore 1997; 1179–1198
   Google Scholar
• Hakomori S-I. Glycolipids of tumor cell membrane. Adv Cancer Res 1973; 18: 265–315
   PubMedGoogle Scholar
• Morton D L, Malmgren R A, Holmes E C, et al. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968; 64: 233–240
   PubMed Web of Science ®Google Scholar
• Morton D L, Eilber F R, Malmgren R A, et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68: 158–164
   PubMed Web of Science ®Google Scholar
• Morton D L, Eilber F R, Holmes E C, et al. BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 1974; 180: 635–643
   PubMed Web of Science ®Google Scholar
• Morton D L, Eilber F R, Holmes E C, et al. Preliminary results of a randomized trial of adjuvant immunotherapy in malignant melanoma. Semin Surg Oncol 1978; 5: 420–435
   Google Scholar
• Morton D L, Nizze J A, Gupta R K, et al. Active specific immunotherapy of malignant melanoma. Current Status of Cancer Control and Immunobiology. Seoul. 1987; 152–161
   Google Scholar
• Irie R F, Irie K, Morton D L. A membrane antigen common to human cancer and fetal brain tissue. Cancer Res 1976; 36: 3510–3517
   PubMed Web of Science ®Google Scholar
• Sidell N, Irie R F, Morton D L. Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen I (OFA-I). I. Complement-dependent cytotoxicity. Cancer Immunol Immunother 1979; 7: 151–155
   Web of Science ®Google Scholar
• Sidell N, Irie R F, Morton D L. Oncofetal antigen I: A target for immune cytolysis of human cancer. Br J Cancer 1979; 40: 950–953
   PubMed Web of Science ®Google Scholar
• Sidell N, Irie R F, Morton D L. Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen-I (OFA-I). II. Antibody dependent cell mediated cytotoxicity. Cancer Immunol Immunother 1980; 9: 49–54
   Web of Science ®Google Scholar
• Irie R F, Jones P C, Morton D L, et al. In vitro production of human antibody to a tumor-associated fetal antigen. Br J Cancer 1981; 44: 262–266
   PubMed Web of Science ®Google Scholar
• Irie R F, Sze L L, Saxton R E. Human antibody to OFA-1, a tumor antigen, produced in vitro by EBV-transformed human B-lym-phoblastoid cell lines. Proc Natl Acad Sci USA 1982; 79: 5666–5670
   PubMed Web of Science ®Google Scholar
• Irie R F, Morton D L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GDI Proc Natl Acad Sci USA. 1986; 83: 8694–8698
   Google Scholar
• Irie R F, Matsuki T, Morton D L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989; 1: 786–787
   PubMed Web of Science ®Google Scholar
• Porloukalian J, Zwingelstein G, Abdul-Malek N, et al. Alterations of gangliosides in plasma and red cells of human bearing melanoma tumors. Biochem Biophys Res Commun 1978; 85: 916–920
   PubMed Web of Science ®Google Scholar
• Portoukalian J, Zwingelstein G, Dore J F. Lipid composition of human malignant tumors at various levels of malignant proliferation. Eur J Biochem 1979; 94: 19–24
   PubMedGoogle Scholar
• Carubia J M, Yu R K, Macala L J, et al. Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 1984; 120: 500–504
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Otsuka H, Niimura M, et al. Biochemical study on gangliosides in neurofibromas and neurofibrosarcomas of Rechlinghausen's disease. J Dermatol 1984; 11: 129–136
   PubMedGoogle Scholar
• Tsuchida T, Ravindranath M H, Saxton R E, et al. Gangliosides of human melanoma: Altered expression in vivo and in vitro. Cancer Res 1987; 47: 1278–1281
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Saxton R E, Irie R F, et al. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 1987; 78: 55–60
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Saxton R E, Morton D L, et al. Gangliosides of human melanoma. J Natl Cancer Inst 1987; 78: 45–54
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Saxton R E, Morton D L, et al. Gangliosides of human melanoma II. Cancer 1989; 63: 1166–1174
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Paulson J C, Irie R F. Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer anten-narins lectin. J Biol Chem 1988; 263: 2079–2086
   PubMed Web of Science ®Google Scholar
• Reivinen J, Holthofer H, Miettinen A. O-Acetyl GD3 ganglioside in human peripheral blood T lymphocytes. Int Immunol 1994; 6: 1409–1416
   PubMed Web of Science ®Google Scholar
• Bauman N, Harpin M L, Turpin J C. Ganglioside content and pattern in tumor tissue of human neuroblastomas. Biomedicine 1981; 35: 215–217
   PubMedGoogle Scholar
• Berra B, Riboni L, De Gasperi R, et al. Modifications of ganglioside patterns in human meningiomas. J Neurochem 1983; 40: 777–782
   PubMed Web of Science ®Google Scholar
• Berra B, Gaini S M, Riboni L. Correlation between ganglioside distribution and histological grading of human astrocytomas. Int J Cancer 1985; 36: 363–366
   PubMed Web of Science ®Google Scholar
• Bouchon B, Portoukalian J, Bomet H. Major gangliosides in normal and pathological human thyroids. Biochem Int 1985; 10: 531–538
   PubMedGoogle Scholar
• Davidsson P, Fredman P, Collins V P, et al. Ganglioside composition in human meningioma. J Neurochem 1989; 53: 705–709
   PubMed Web of Science ®Google Scholar
• Fredman P, Von Hoist B, Collins V P, et al. Potential ganglioside antigen associated with human gliomas. Neurol Res 1986; 8: 123–126
   PubMedGoogle Scholar
• Goff B A, Lee W MF, Westrick M A, et al. Gangliosides of human chronic lymphocytic leukemia and hairy cells. Eur J Biochem 1983; 130: 553–557
   PubMedGoogle Scholar
• Higashi H, Hirabayashi Y, Hirota M., et al. Detection of ganglioside GM2 in sera and tumor tissues of hepatoma patients. Jpn J Cancer Res 1984; 78: 1309–1313
   Google Scholar
• Higashi H, Hirabayashi H, Sasabe T, et al. Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 1988; 79: 952–956
   PubMedGoogle Scholar
• Kanda S, Cochran A J, Lee W, et al. Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity and malignant potential. Int J Cancer 1992; 52: 682–687
   PubMed Web of Science ®Google Scholar
• Ladisch S, Wu Z L. Detection of a tumor-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1985; 1: 136–138
   PubMed Web of Science ®Google Scholar
• Liepkalns V A, Icard C, Yates A J, et al. Effects of cell density on lipids of human glioma and fetal neural cells. J Neurochem 1981; 36: 1959–1965
   PubMed Web of Science ®Google Scholar
• Miyake M, Hashimoto K, Ito M, et al. The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. Cancer 1989; 65: 499–505
   Web of Science ®Google Scholar
• Schengrund C, Repman M A, Shochat S J. Ganglioside composition of human neuroblastomas. Correlation with prognosis. Cancer 1985; 56: 2640–2646
   PubMed Web of Science ®Google Scholar
• Shochat S J, Abt A B, Schengrund C L. VCN-releasable sialic acid and gangliosides in human neuroblastomas. J Pediatr Surg 1977; 12: 413–418
   PubMed Web of Science ®Google Scholar
• Siddiqui B, Buehler J, Degregorio M W, et al. Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res 1984; 44: 5262–5267
   PubMed Web of Science ®Google Scholar
• Sunder-Plassman M, Bernheimer H. Ganglioside in meningiomen and heinhauten. Acta Neuropathol 1974; 27(Berl)289–294
   PubMedGoogle Scholar
• Traylor D L, Hogan E L. Gangliosides of human cerebral astrocytomas. J Neurochem 1980; 34: 126–131
   PubMed Web of Science ®Google Scholar
• Westrick M A, Lee W MF, Goff B, et al. Gangliosides of human leukemia cells. Biochim Biophys Acta 1983; 750: 141–146
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Tsuchida T, Morton D L, et al. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991; 67: 3029–3035
   PubMed Web of Science ®Google Scholar
• Gullino P M. Prostaglandins and gangliosides of tumor microenvi-ronment: their role in angiogenesis. Acta Oncol 1995; 34: 439–441
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Morton D L, Irie R F. An epitope common to gangliosides O-acetyl GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 1989; 49: 3891–3897
   PubMed Web of Science ®Google Scholar
• Cheresh D A, Harper J R, Schulz G, et al. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci US A 1984; 81: 5767–5771
   PubMed Web of Science ®Google Scholar
• Morton D L, Foshag L G, Hoon D SB, et al. Prolongation of survival in metastatic melanoma following active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 462–482
   Google Scholar
• Ravindranath M H, Ravindranath R MH, Morton D L, et al. Factors affecting the fine specificity and sensitivity of serum antigan-glioside antibodies in ELISA. J Immunol Methods 1994; 169: 257–272
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Guenther M, Kunnath S, et al. Anti-ganglioside IgM responses to a new melanoma cell vaccine (MCV) in melanoma patients. Proc Am Assoc Cancer Res 1993 1993; 34: 488
   Google Scholar
• Morton D L, Ravindranath M H, Irie R F. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Prog Brain Res 1994; 101: 251–275
   PubMed Web of Science ®Google Scholar
• Tai T, Cahan L D, Tsuchida T, et al. Immunogenitcity of melanomaassoicated gangliosides in cancer patients. Int J Cancer 1985; 35: 607–612
   PubMed Web of Science ®Google Scholar
• Livingston P O, Calves M J, Natoli E F. Approaches to augmenting immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells. J Immunol 1987; 138: 1524–1529
   PubMed Web of Science ®Google Scholar
• Livingston P O, Natoli E J, Calves M J, et al. Vaccines containing purified GM2 gangliosides elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 2911–2915
   PubMed Web of Science ®Google Scholar
• Livingston P O. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to gan-glioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 147–166
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Hoegan P V. Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines. Vaccine Res 1994; 2: 183–196
   Google Scholar
• Ravindranath M H, Morton D L, Irie R F. Attachment of mono-phosophoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides. J Autoimmun 1994; 7: 803–816
   PubMed Web of Science ®Google Scholar
• Bogoch S. Demonstration of serum precipitin to brain gangliosides. Nature 1960; 183: 392–393
   Google Scholar
• Shy M E, Evans V A, Lubin F D. Antibodies to GM1 and GD1b in patients with motor neuron disease with plasma cell dyscrasia. Ann Neurol 1989; 25: 511–518
   PubMed Web of Science ®Google Scholar
• Naiki M, Marcus D, Leeden R. Properties of antisera to ganglioside GM1 and asialo-GM1. J Immunol 1974; 113: 84–93
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Trams E G, Brady R O. Immunochemical studies with gangliosides. J Immunol 1963; 113: 84–93
   Google Scholar
• Sherwin A I, Lowden J A, Wolfe L S. The production of antisera to gangliosides from human nervous tissue. J Biochem 1964; 42: 1640–1648
   Web of Science ®Google Scholar
• Pascal T A, Saifer A, Gitlin J. Immunochemical studies on normal and Tay-Sachs brain gangliosides. Proc Sec Exp Biol Med 1966; 121: 739–743
   PubMed Web of Science ®Google Scholar
• Koscielak J, Hakomori S-I, Jeanloz R W. Glycolipid antigen and its antibody. Immunochemistry 1968; 5: 441–455
   Google Scholar
• Helling F, Shang Y, Calves M, et al. Increased immunogenicity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 1993; 54: 197–203
   Google Scholar
• Portoukalian I, Carrel S, Dore J F, et al. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associatedgangliosides. Int J Cancer 1991; 49: 893–899
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ono K, Hirabayashi Y, et al. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol 1988; 140: 3244–3249
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Brazeau S M, Morton D L. Efficacy of tumor cell vaccine after incorporating monophospnoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Experientia 1994; 50: 648–653
   PubMedGoogle Scholar
• Maliakal M A, Ravindranath M H, Irie R F, et al. An improved method for the measurement of total lipid-bound sialic acid after cleavage of α2,8 sialic acid linkage with Vibrio cholerae sialidase in the presence of cholic acid, SDS and CA2+. Glycoconjugate J 1994; 11: 97–104
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Bauer R, Amiri A A, Miri S M, Kelley M C, Jones R C, Morton D L. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (Sialyl Lea, sialyl Le2, GD3 and GM2) better than soluble lysate cancer vaccine. Anticancer Drugs, 8: 217–224
   PubMed Web of Science ®Google Scholar
• Ravindranath M H, Amiri A A, Bauer P M, Kelley M C, Essner R, Morton D L. Endothelial-selectin ligands Sialyl Lewisx and Sialyl Lewisa are differentiation antigens immunogenic in human melanoma. Cancer, 79: 1686–1697
   PubMed Web of Science ®Google Scholar